BCAX · Bicara Therapeutics Inc.
$17.59
+0.33 (+1.88%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$1.17B
Shares
66.17M
Volume · Oct 9
170.76K
Avg daily vol (3M)
620.37K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.26
Open$16.32
Day$15.85–17.33
52W close$13.93–30.40
Avg vol 30d673K
Short int11.2M · 16.9% float · 22.6d
Short vol59%
Last earningsAug 11, 2026
DataSep 2024–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Oct 12, 2026
Est · unconfirmed
· this week
filed Aug 11, 2026
call held Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-9.6%
Trailing year
Short interest
16.9%
Latest settlement · 22.6 days to cover
AI Brief
Q2 FY26 earnings call · Aug 11, 2026
Q2 FY26
TL;DR. Bicara reported that its pivotal Phase 3 FORTIFI-HN01 study of ficerafusp alfa remains on track for substantial enrollment by year-end and a mid-2027 interim analysis, with three-year follow-up data presented at ASCO showing an estimated 31% OS rate, while announcing a planned CEO transition and a higher quarterly net loss of $55.4M as operating expenses nearly doubled.
Bullish
- + On track for substantial enrollment of FORTIFI-HN01 by year-end with interim analysis in mid-2027, supporting potential accelerated approval.
- + Initiated FORTIFI-FLEX alternative dosing study with data expected by time of potential U.S. accelerated approval.
- + ASCO three-year follow-up showed an estimated 31% OS rate at the 1500mg QW pivotal dose, approximately doubling standard-of-care pembrolizumab in HPV-negative patients.
- + Cash position of $497.3M provides runway into the first half of 2029.
- + Planned leadership transition installs President/COO Ryan Cohlhepp as CEO effective January 2027 to lead commercial readiness, with new CCO, CFO, CLO and other appointments.
Bearish
- − Net loss widened to $55.4M in Q2 2026 from $27.4M in Q2 2025.
- − Total operating expenses nearly doubled to $59.95M in Q2 2026 from $32.02M in Q2 2025, driven by pivotal study costs and headcount growth.
- − Management guided to continued quarter-over-quarter operating expense increases for the remainder of the year as commercial and medical affairs build-out accelerates.
- − Founder/CEO Claire Mazumdar is transitioning to Vice Chair/Strategic Advisor ahead of the pivotal interim readout, introducing leadership-transition risk into the most important data window.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−24%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
20%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−25%
trailing
6-month return
−28%
trailing
YTD return
+3%
this year
Relative strength
−37%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $23 › 200d $21 — 50d above 200d
Institutional flow
Distributing
4 of 175 funds reported for Sep 30 · net -87 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.91% of float · ▲ +3.2% MoM · 22.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
175 holders — near 2-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
EPS growth
+38%
Y/Y
Free cash flow
$-107.1M
Quant / Vol
risk profile
Volatility
56%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−24%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
20%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $23 › 200d $21 — 50d above 200d
Institutional flow
Distributing
4 of 175 funds reported for Sep 30 · net -87 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
16.91% of float · ▲ +3.2% MoM · 22.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
175 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $14
Now $17 · 20%
Range high $30
vs 200-day avg -19%
vs 50-day avg -24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCAX
this stock
Bicara Therapeutics Inc.
|
$1.17B | +2.6% | — | — | 16.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +11.0% | +46.2% | 29.3 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCAX | -5.2% | -25.3% | -28.1% | -7.3% | +2.6% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -6.5% | -27.4% | -37.1% | -8.7% | -10.9% |